Blinatumomab is a type of immunotherapy known as a bispecific T-cell engager (BiTE) antibody. This drug is designed to direct the body's own immune system to attack cancer cells. Specifically, it binds to CD19, a protein found on the surface of B-cell lymphomas and leukemias, and CD3, a protein on T-cells, effectively bringing T-cells in proximity to cancer cells to induce cell-mediated cytotoxicity.
